Rare Disease Treatment Company Set to Acquire for 6 Trillion Won, Surpassing 800 Billion in Annual Revenue

Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported $634.2 million in 2025 revenue, a 17% year-over-year increase driven by higher sales of Galafold and its Pompe disease combination therapy, Pomfility Plus Opfolda. The company narrowed its GAAP net loss to $27.1 million while delivering a non-GAAP net profit of $96.8 million. Cash and marketable securities rose to $293.5 million.

Amicus reaffirmed its agreement to be acquired by BioMarin at $14.50 per share—an aggregate deal value of $4.8 billion. Following an HSR filing on January 21, the U.S. Federal Trade Commission terminated its waiting period early on February 11, clearing the way for the transaction to close in the second quarter of 2026. In light of the pending acquisition, Amicus will not provide full-year 2026 guidance or host its customary quarterly earnings conference calls.

The acquisition is part of BioMarin’s $4.8 billion strategy, announced in December 2025, to strengthen its rare-disease portfolio. Upon closing, BioMarin plans to integrate Galafold and Pomfility Plus Opfolda into its existing rare-disease lineup. Reflecting optimism around the deal and continued revenue growth, FOLD shares hit a 52-week high in December 2025, though they have exhibited volatility since.

Based in New Jersey, Amicus is a biotech company specializing in treatments for rare genetic disorders. It has commercialized the oral Fabry disease therapy Galafold and the Pompe disease combination treatment Pomfility Plus Opfolda. Despite serving a small patient population, the rare-disease market is notable for high unmet medical needs and premium pricing, making it a focal point for acquisitions and partnerships among global pharmaceutical firms.